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Letter to the Editor
Frameshift mutations in Fas, Apaf-1, and Bcl-10 in
gastro-intestinal cancer of the microsatellite mutator
phenotype
Dear Editor,
In a letter to the editor in a recent issue of Cell Death and
Differentiation, Abdel-Rahman et al1. reported the absence of
mutations in the death pathways gene Fas (Apo-1/CD95) in
colorectal carcinomas. From the absence of mutations in 24
colon cancers, 12 of which were classified as replication error
positive (RER+), Abdel-Rahman et al1. concluded that such
mutations confer no substantial growth advantage in color-
ectal carcinogenesis. In agreement with this report, we
identified Fas mutations in only 10% of colon and gastric
cancers of the microsatellite mutator phenotype (MMP), also
denominated as RER or microsatellite instability (MSI).
Mutations were also found in Apaf-1 and Bcl-10, two other
genes involved in the cell death pathways. The mutations
were detected in mononucleotide tracts within these three
genes (Figure 1). The frequency of these frameshift mutations
was low (Table 1) and they appeared to be heterozygous
(Figure 2). However, considering the peculiar features of
these tumors, we suggest that these frameshift mutations
contribute to cancer progression by providing survival
advantage.
Figure 1 Position of mononucleotide tracts in pro-apoptotic genes Fas, Apaf-1 and Bcl10. Frameshift mutations at these positions are likely to inactivate protein
function because the resulting truncations eliminate functional domains for apoptosis in each of these three genes.7 ± 9 FAS plays an apoptotic role in response to c-
Myc, DNA damage and T-cell mediated cytotocixity, through the caspase cascade.7,10 Apoptotic protease activating factor-1 (APAF-1) is a proximal activator of
caspase-9 in cell death pathways that trigger mitochondrial damage and cytochrome c release.8,11 Bcl10 is involved in the execution of apoptosis.9,12,13 No
mutations have been described in Apaf-1 in human cancer. A low frequency of missense mutations in Fas has been described in several human malignancies.14 ± 16
Mutations in Bcl10 have been found in several cancers, including colon cancer cell lines.9,13,17 A similar truncated form of Apaf-1 (codons 1 ± 570) fails to induce
apoptosis and to activate pro-caspase-3.18 Although frameshift mutations in these genes could have a negative dominant effect since these proteins oligomerize, we
favor an alternative accumulative haploinsufficiency hypothesis (see text). TM: Transmembrane domain; CARD: Caspase recruiting domain. Positions of stop codons
after frameshifts are indicated in italics by dots (+1 and 71 bp, above and below, respectively). Not to scale
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The MMP pathway for gastrointestinal cancer presents
two paradoxical features at first sight. First, despite
accumulating hundreds of thousands of clonal somatic
mutations in simple repeated sequences, these tumors
exhibit a low mutation incidence in APC, K-ras and p532
prototypical cancer genes for colorectal carcinogenesis.3
Second, while ubiquitous mutations in non-functional poly
(A)n sequences (such as the poly A tails of the Alu
repeats), are biallelic,2 these tumors also accumulate
many monoallelic (i.e. heterozygous) mutations in func-
tional sequences, such as the coding regions of mutator
(hMSH3, hMSH6),4 suppressor (p53, TGFbRII)2,5 and
apoptotic (Bax)6 genes. In contrast, the manifestation of
the tumor phenotype by cancers without the MMP is
usually associated to the biallelic mutational inactivation of
a few cancer genes such as APC and p53 tumor
suppressors.3
The first paradox may be explained by the existence
within some genes of simple repeats which are preferred
targets for the MMP. Thus, in the presence of the mutator
phenotype, mutations in these genes (i.e. Bax) occur
sooner than in other genes of the same oncogenic (i.e.
apoptotic) signaling pathways that do not have these
repeats (i.e. p53).6 We propose here a model to explain
the second paradox. Due to the exacerbated mutator
phenotype of these tumors, their ability for escaping
apoptosis may be facilitated by the accumulation of
heterozygous mutations in multiple genes whose products
play partially redundant and partially synergistic roles at
different points of the apoptotic signaling network. This
accumulation of heterozygous mutations presumably
reduce the homeostatic threshold amount of the corre-
sponding pro-apoptotic gene products.
In agreement with this hypothesis, most MMP+ tumors
had frameshift mutations in more than one of these genes
(Figure 2). Due to the still limited knowledge of the human
genome and the strong mutator phenotype of these tumors,
it appears very unlikely that these are the only death
pathway genes mutated in cancer of the MMP. This
accumulative haploinsufficiency model is not restricted to
apoptotic pathways, but also applies to other networks
involved in the homeostatic control of genome integrity and
cell proliferation.
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Figure 2 Frameshift mutations in apoptotic genes in colon tumors of the
microsatellite mutator phenotype. The position and size of the wild-type PCR
product are indicated at right, and triangles pointing up or down indicate
insertions or deletions of one nucleotide. T and N: tumor and adjacent normal
colon tissues. Frameshift mutations in Bax and Caspase 5 have been
previously described.6,19,20 No other caspases were analyzed for mutations
because they do not have mononucleotide tracts in the coding regions of
sufficient length (7 or more bp). The only exception is Caspase 1, which has a
(A)8 tract, but no mutations were found.
19 Amplification of Bax and caspase-5
and analysis by polyacrylamide gel electrophoresis and autoradiography, was
as described.6,19,20 Amplification of Fas, Apaf-1 and Bcl10 was done with up
and down PCR primers: 5' ACC CAG AAT ACC AAG TGC AG 3' and 5' TGC
AAG GGT CAC AGT GTT CA 3' for Fas; 5' GTT ACT TTT TTC CCT GTA TTT
AGA AAC 3' and 5' TAT TCT CTG ACC ATC CTC AG 3' for Apaf-1; and 5' CAT
AGC TGA GAG ACA TTT TG 3' and 5' AGC CCT TTT TCT ACT TGA TG 3' for
Bcl10
Table 1 Frameshift mutations in 30 colon and 20 gastric MMP+ cancers were
analyzed by PCR ampli®cation of the coding regions ¯anking the mononucleotide
tracts present in these genes (Figure 1)
Colon Gastric
Fas
Apaf-1
Bcl-10
3 (10%)
4 (13%)
4 (13%)
2 (10%)
3 (15%)
2 (10%)
Frameshift mutations in these three apoptotic genes were absent in 60 colon
cancers without the MMP. Even in the presence of the MMP, the mutation rates
in these short repeated sequences appear to be below detectable limits in the
absence of a positive selection, because no mutations are found in many
repeated sequences of identical length in noncoding regions nor in other genes
not implicated in cancer6,19,20
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